Nguyen D, Herrmann T, Hartl B, Draganov D, Minev I, Neuharth F
Cancers (Basel). 2022; 14(24).
PMID: 36551636
PMC: 9777144.
DOI: 10.3390/cancers14246136.
Plaza-Rojas L, Guevara-Patino J
Front Immunol. 2021; 12:624131.
PMID: 33717132
PMC: 7952755.
DOI: 10.3389/fimmu.2021.624131.
Hu W, Wang G, Wang Y, Riese M, You M
iScience. 2020; 23(10):101580.
PMID: 33083746
PMC: 7554032.
DOI: 10.1016/j.isci.2020.101580.
Riding R, Richmond J, Fukuda K, Harris J
Pigment Cell Melanoma Res. 2020; 34(4):683-695.
PMID: 33040466
PMC: 8035367.
DOI: 10.1111/pcmr.12935.
Qin Q, Wang J, Wang H
Zhongguo Fei Ai Za Zhi. 2020; 23(9):772-791.
PMID: 32752580
PMC: 7519956.
DOI: 10.3779/j.issn.1009-3419.2020.104.07.
Recombinant Poxvirus and the Tumor Microenvironment: Oncolysis, Immune Regulation and Immunization.
Sharp D, Lattime E
Biomedicines. 2017; 4(3).
PMID: 28191451
PMC: 5298125.
DOI: 10.3390/biomedicines4030019.
Viruses as nanomedicine for cancer.
Badrinath N, Heo J, Yoo S
Int J Nanomedicine. 2016; 11:4835-4847.
PMID: 27703350
PMC: 5036661.
DOI: 10.2147/IJN.S116447.
The genetics of vitiligo.
Spritz R
J Invest Dermatol. 2011; 131(E1):E18-20.
PMID: 22094401
PMC: 3513341.
DOI: 10.1038/skinbio.2011.7.
New perspectives on the role of vitiligo in immune responses to melanoma.
Byrne K, Turk M
Oncotarget. 2011; 2(9):684-94.
PMID: 21911918
PMC: 3248219.
DOI: 10.18632/oncotarget.323.
Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma.
Byrne K, Cote A, Zhang P, Steinberg S, Guo Y, Allie R
J Clin Invest. 2011; 121(5):1797-809.
PMID: 21540555
PMC: 3083789.
DOI: 10.1172/JCI44849.
The effect of attenuated vaccinia virus AS strain on N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric cancer in rats.
Arakawa S, Fukai K
J Cancer Res Clin Oncol. 1983; 105(2):117-26.
PMID: 6826635
DOI: 10.1007/BF00406921.
Immune responses of DBA/2 mice bearing melanoma tumors: cell-mediated immune responses after challenge with vaccinia virus.
Byrne J, Soloski M, Holowczak J
Cancer Immunol Immunother. 1983; 16(2):81-7.
PMID: 6607104
PMC: 11039053.
DOI: 10.1007/BF00199236.
Immunity to malignant disease in man.
Fairley G
Br Med J. 1969; 2(5655):467-73.
PMID: 5771576
PMC: 1983396.
DOI: 10.1136/bmj.2.5655.467.
[Studies on the effect of smallpox vaccine and Freund's adjuvant on the Harding-Passey melanoma in the mouse].
Schwab B
Arch Dermatol Forsch. 1971; 241(4):411-25.
PMID: 5127773
[Immunologic analysis of tyrosinase in malignant melanoma, nevi and clinically normal skin].
HERRMANN W
Arch Dermatol Forsch. 1971; 241(1):65-74.
PMID: 4997883
Use of vaccinia virus in the treatment of metastatic malignant melanoma.
Newton K, Westbury G, Lacey B
Br Med J. 1970; 2(5708):512-5.
PMID: 4913781
PMC: 1700360.
DOI: 10.1136/bmj.2.5708.512.
Infection of DBA/2 or C3H/HeJ mice by intraperitoneal injection of vaccinia virus elicits activated macrophages, cytolytic and cytostatic for S91-melanoma tumor cells.
Natuk R, Byrne J, Holowczak J
Cancer Immunol Immunother. 1986; 22(3):197-203.
PMID: 3731205
PMC: 11038435.
DOI: 10.1007/BF00200033.
Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates.
Hersey P, Edwards A, Coates A, Shaw H, McCarthy W, MILTON G
Cancer Immunol Immunother. 1987; 25(3):257-65.
PMID: 3677126
PMC: 11038013.
DOI: 10.1007/BF00199156.
Vitiliginous achromia with malignant melanoma. Tyrosinase activity and ultrastructural study of achromic and normal skin.
Perrot H, Ortonne J, Schmitt D
Arch Dermatol Res (1975). 1977; 257(3):247-53.
PMID: 402121
DOI: 10.1007/BF00741840.
The role of immunotherapy in the management of patients with malignant melanoma.
Goodnight Jr J, Morton D
World J Surg. 1979; 3(3):309-20.
PMID: 382645
DOI: 10.1007/BF01556582.
